Takeda Pharmaceutical Upgrades FY 2026 Outlook Following Strong First-Half Results
Takeda Pharmaceutical reported strong first-half financial results, highlighted by a non-GAAP earnings per share (EPS) of ¥308.00 and total revenue of ¥2,407 billion, representing an 8.4% increase year-over-year. The company also reported adjusted free cash flow of JPY 325.7 billion during this period. Driven by favorable foreign exchange impacts, Takeda has officially upgraded its full-year guidance for fiscal year 2026. This upward revision reflects the company's improved financial positioning and provides a more optimistic outlook for investors regarding long-term profitability and cash flow generation.
Tickers: $TAK
Topics: earnings report free cash flow guidance upgrade revenue growth
Read the full article at Seeking Alpha
Part of the story Takeda Pharmaceutical Upgrades FY 2026 Outlook Following Strong First-Half Results (4 articles)